FDA Releases MannKind from Major Afrezza Postmarketing Study; Pediatric Decision Due Tomorrow
MNKD sits 64% above its 52-week low of $2.23.
Summary
The FDA has released MannKind from the five-year pulmonary malignancy postmarketing study for its drug Afrezza, removing a significant regulatory burden and de-risking the product. This follows the 8-K filed earlier today. Additionally, the company faces a PDUFA date tomorrow, May 29, 2026, for the pediatric efficacy and safety assessment of Afrezza for ages 4-17. A positive decision could expand Afrezza's market. The PDUFA decision tomorrow is a key event to watch.
At the time of this announcement, MNKD was trading at $3.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $2.23 to $6.51. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.